Osaka University, Japan Japan
University of Arizona, USA USA
National Institutes of Health, USA USA
University of Houston, USA USA
University of Nebraska Medical Center, USA USA
Osaka University, Japan Japan
Michigan State University, USA USA
Shizuoka University, Japan USA
Recommended Global Chemistry Conferences
MedChem & MTDD 2018
Conference Series welcome professional chemists, researchers, professors, scientific communities, delegates, students, business professionals and executives from all over the world to attend the 19th International Conference on Medicinal Chemistry and Multi-Targeted Drug Delivery scheduled during November 05-06, 2018 in San Francisco, USA
Medicinal chemistry explores different ways how chemists are modifying molecules structure so as to design innocuous and effective drugs. It is one of the most rapidly developing areas within chemistry, both globally and locally.The different spectroscopic techniques for drug design, synthesis and characterization of novel therapeutic agents including small molecules, peptide drugs and natural products will be discussed. Applications in novel methods of drug delivery systems and formulations for better bioavailability of bioactive compounds are also welcomed
Medchem And MTDD will likewise give the fantastic chance to meet specialists, trade data, and reinforce the coordinated effort among Directors, Researchers, Associate Professors, and Scholars from both scholarly community and industry.
Medchem And MTDD will cover all areas of Medicinal chemistry
Conference Highlights are:
· Medicinal Chemistry and Drug Discovery
· Principles of Medicinal Chemistry
· Medicinal Chemistry Aspects of Drug Action and Drug Metabolism
· Drug Metabolism
· Molecular Biology - A New Route to Drug Discovery
· Fusion of Traditional And Biomedicine
· Plant Genomics
· Pharmaceuticals Vs Nutraceuticals
· Frontiers In Chemistry
· Computer Aided Drug Designing
· Drug Chemistry
· Hyphenated Chromatographic Techniques
· Cancer Studies: Drug Delivery Chemistry
· Neuro Degenerative Disease
· Vaccines And Autism
· Emerging Infectious Diseases
· Eminent Scientific Professionals in Pharma and Chemistry
· Faculty (Professors, Associate Professors, Asst. Professors )
· Pharma and Chemistry Colleges & Training Institutes
· Pharmaceutical and Chemistry Associations and Societies
· Pharmaceutical Business Entrepreneurs
· Manufacturing Pharmaceutical products Companies
· Manufacturing Medical Devices Companies
· Pharma and Chemistry Students
· PhD Scholars, Graduates and Post Graduates
· Directors, CEO’s of Organizations
· Association, Association presidents and professionals
· Noble laureates in Health Care and Medicine
· Bio instruments Professionals
· Bio-informatics Professionals
· CRO and DATA management Companies
· Data Management Companies
ConferenceSeries organises 800+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies and publishes 400+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
For abstract submission please click: https://medicinalchemistry.pharmaceuticalconferences.com/abstract-submission.php
We are eagerly waiting to meet you at San Francisco, California for the MedChem & MTDD 2018 Meeting
Sessions / Tracks
- Target discovery and validation
- Molecular modelling
- Drug receptor interactions
- Pro drug synthesis and drug targeting
- Structure and Fragment based drug design
- Organic synthesis of ligands and inhibitors
- Protein biochemistry.
- Development of screening and assay methods.
- Molecular biology and genetic engineering.
- Drug-Receptor Interactions
- Signal Transduction and Second Messengers
- The Biological Evaluation of New Compounds
- Considerations for the Use of Computational Chemistry Techniques by Medicinal Chemists
- Research strategies
- Methodologies and literature concerning the mechanisms of drug action and drug metabolism
- Mechanisms of drug action and drug metabolism in opiate drugs and beta blockers
- NS3, the protease of flaviviruses such as dengue and West Nile virus
- Combined phenotypic/target-oriented screening approaches, and their application on anti-infective drug discovery
- Targeting of host factors involved in virus replication
- Biochemical mechanisms for the biotransformation of drugs and foreign compounds
- reaction mechanisms
- Ultrastructural considerations,induction mechanisms, methodology, kinetics of inhibition
- Activation, steroid and amine metabolism.
- DNA Structure
- What Determines the Differences between Cell Types
- Gene Cloning - Propagation of Genetic Material in Alternative Host Systems
- Expression of Cloned Genes
- Uses of Cloned Human Proteins
- Personalized Medicine
- Naturopathy and Acupuncture as a secondary medical system
- Drug resistance by misuse of medications
- Modernising Traditions
- Protection and piracy
- Plant-pathogen interactions
- Breeding strategies to enhance yield
- Hybrid vigor
- DNA microarrays
- Advances in plant Tissue culture and revolutionizing agriculture
- Plant biotech for agriculture Improvement
- Can only drug cure a disease?
- Why are pharmaceuticals around?
- Nutraceutical Supplements as convenient and effective
- Bridging the gap between food and medicine
- Peptides with dual Antimicrobial and anticancer activities
- Anticancer activitiy of maize Bioactive peptides
- Contemporary materials safety
- The 'making a murderer 'case:A brief description on how EDTA is measured in blood
- Ligand and structure based drug design
- Computational Chemistry
- Molecular modelling
- Enzyme as target
- Receptor as target
- QSAR/QSPR Quantitative structure activity/property relationships
- Platinum based anticancer drugs
- Objectives of TDDS
- Bioligand and its attachement to protein target
- Passive ,Inverse and Active approaches of targeting
- Chemical and physical enhancer pathways
- ADME (adsorption,distribution,metabolism and excretion)Of drugs
- Metabolism and toxicology
- Antiviral and antimicrobial activity
- Drug receptor interaction
- Kojic acid as a tyrosine inhibitor
- Magnetoelectric nanoparticles
- Nanoparticle drug delivery
- Problems of multidrug resistance in cancer therapies
- Taxoids as potent cytotoxic agents for tumour targeting drug delivery
- Dementias responsible for greatest burden of neurodegenerative diseases
- Causes and treatments
- Motor neurone diseases
- Huntington’s disease.
- A pattern of depressed resistancein autism
- Do vaccines for children cause autism?
- Research supports vaccinating
- Autism genetic risk factors
- Autism environmental risk factors
- Determinants of Infectious diseases
- Emergence and Reemergence of infectious diseases
- HIV/AIDS:Newly emerging infectious diseases
- Research on emerging Infectious diseases
- Preventing emerging infectious diseases:A strategy for the 21st century
- Zika virus
- How do antibiotics work?
- What are the side effects?
- Main types of antibiotics
- Biological antibiotics derived from molds
- Synthetic antibiotics derived from dyes
- Antibiotic resistance and meggence of 'superbugs'
- Personalised medicines:A decade of advancements
- Cancer genomics
- Good for patients but bad for drug companies
- Ramifications of illicit drug markets in society
- Chemotherapeutic agents
- Microorganisms that produce antibiotics
- Antimicrobialpeptides:Promising compounds against pathogenic microorganisms
- Discovery of penicillin
- Discovery of sulphonamides
- Rapid Transmission
- ZIKV-Processing on the microfluidic cassette
- ZIKA virus infection may prevent reinfection
- Zika infection-A global threat to human population
- Major possible symptoms
- Drugs and vaccines available so far
- Binding kinetics and pathways of ligands to GPCRs
- Aurora A kinase ,a priority pharmaceutical target for treatment of cancer
- Novel adjuvants designed for improving vaccine efficacy
- Targetting Protease-activated receptors(PAR1)
- Risks associated with new drug development
- Role of computational biology
- Drug delivery carriers
- Pioneering digital health and smart drug delivery systems
- Ligand binding studies
- Phage display technology for clinical application of protein drugs
- Potential use of stem cells for regeneration
- Harnessing yeast organelles for metabolic engineering
- Si-RNA a tool in chemical biology
- Discovery of biomolecules through metagenomics
- High throughput screening
- Target identification
- Target validation
- Assay development
- Screening cascade-Lead optimization
- Application of integrated data from the physical and biological sciences to problems of chemotherapy
- Transport of drugs to site of action
- Biotransformation of drugs
- Interaction of drugs with enzyme systems
- Recent advances in drug design
- New Drugs to Eliminate Malaria
- Breakthrough in the Treatment of Cancer
- New Strategy for the Discovery of Drugs
- New Drug Discovery Technique to Target a Class of Enzymes
- Serelaxin - Breakthrough Therapy in the Treatment of Heart Failure
- Vertex Pharmaceuticals’ New Drug Combination can Treat Cystic Fibrosis
- Promising Treatment for Multiple Sclerosis
- Discovery of Ebola Protein could Lead to Drug Development
- New Drug could Treat Most Aggressive Form of Lung Cancer
- Medicinal chemistry of drugs used in diabetic cardiomyopathy.
- Advantages of fluorine in drug development
- Fluorinated drugs in the central nervous system (CNS)
- Fluorinated drugs in the treatment of metabolic and cardiovascular diseases
- Fluorinated drugs in the treatment of cardiovascular diseases
- Fluorinated antibacterial agents
- Fluorinated azole antifungal agents
- Fluorinated anti-inflammatory agents
- Fluorinated anticancer agents
- Current problems in human drug metabolism by cytochrome P-450 enzymes
- Hypothesis testing and experimental problem solving in the areas of enzyme kinetics and mechanism
- Mechanisms of action
- spectrum of coverage, resistance patterns
- Toxicity, and therapeutic applications of antibiotics, antifungals, and antivirals
- chemical and biologic properties of agents used to prevent or treat infectious diseases
- Therapeutic antibodies, and drug targets
- Protein-protein-interactions and Protein-lipid interaction.
- Thermodynamics and kinetics of protein-ligand interactions,
- Integrates aspects of medicinal chemistry and pharmacokinetics with the physiology, Pharmacology, and genetics of therapeutic drug targets.
- Include ion channels and enzymes relevant to cardiovascular disease
- Include ion channels and enzymes relevant neurodegenerative disease
- Biological Mass Spectrometry
- Modern ionization methods and mass analyzers
- Small molecule structure assignment
- Quantitative assay development by LC-MS and metabolomics quantitative discovery-based proteomics and validation methods
- Peptide sequence determination
- Post-translational modification mapping
- Protein structure determination methods
- Design and synthesis of target compounds: thiazoles, thiophenes, benzimidazoles and boronic acid derivatives as anticancer and anti-diabetic agents.
- Synthesis of neuroprotective and multi target directed ligand molecules and their pharmacokinetic/pharmacodynamic (PK/PD) studies.
- Ionic liquid mediated C-C and C=C bond forming reactions.
- Re purposing of existing drug molecules for improved PK/PD profiling by modification of non pharmacophoric parts.
- Transition metal catalyzed C-H activation reactions of unreactive (C(sp2)-H, C(sp3)-H bond) for the synthesis of anticancer agents.
- Monoclonal antibodies
- Non-specific immunotherapies
- Oncolytic virus therapy
- T-cell therapy
- Cancer vaccines
Track 36: Sources of leads
- Lead selection from HTS and virtual screening
- General design principles
- Drug design with defined target structure
- Drug design without defined target structure
- ADMET Optimization
- High resolution-mass spectrometry (HR-MS) technology
- Data-mining tools
- Data-acquisition techniques.
- AB SCIEX TripleTOF™ 5600 System for the study of drug metabolism in BDC rats and CYP inhibition cocktail assays.
- Histone deacetylases (HDACs) and histone acetylases (HATs)
- Leukaemia-associated fusion proteins
- Leukaemia-associated fusion proteins HDAC inhibitors
- Tumour-necrosis factor-related Apoptosis-Inducing Ligand (TRAIL) and FAS death receptor pathways
- Nanoparticles that deliver three anti-cancer drugs to the lymph nodes
- Sustained drug delivery using a hydrogel
- Photosensitizing agent to enhance the ability of drug carrying nanoparticles
- Carbon nanofibers penetrate diseased cells
- Nanotechnology in Drug Delivery - Heart Disease:
- Nanotechnology in Drug Delivery - Aging and other areas
- Survey of major drug classes with emphasis on molecular mechanisms of action
- Target identification with chemical probes
- Survey of methods used in contemporary pharmaceutical research including computational and combinatorial approaches
- High-throughput analysis of drug efficacy and metabolism
Market: Opportunities and Competitive Dynamics
It has been estimated that in the field of Medicinal chemistry more than $79 million has spent in research funding since 2008. A complete overview of drug designing process with comparison to conventional approaches of drug discovery has come up with some crucial details, which says that from year 2008 to 2013 the market has grown to $198 billion and in further this rate may increases to $236 Billion from year 2014 to 2019. Special emphasis has given on computational approaches for drug discovery along with salient features and applications of the software’s used in novel research studies.
The hugest test in this industry is to reduce the quantity of medications that bomb in pre-clinical stages, as this encourages the maker to enter the market with a profligate medication. Be that as it may, since the ADME profiling utilized as a part of silico and cell approaches have effectively lessened the weakening rate. As per industry specialists as of now structure-based medication configuration has high acknowledgment took after by part based variety, common items, while decent variety situated blend and chemo genomics have unimportant pieces of the overall industry. The best five dynamic restorative research regions are tumour, contaminations, neurological, gastrointestinal, endocrine and cardiovascular.
Medication revelation is relied upon to be to a great extent polished at little specialty biopharmaceutical organizations around the globe in the U.K., U.S., Western Europe, Eastern Europe, China, India, Brazil, South Africa and Mexico as speculations, time and dangers are similarly less in this operations demonstrate than the customary. Generally speaking the restorative science has enhanced every one of these years with all refreshed advances and procedures.
The significance of little and medium scaled organizations will increment in this market as it will diminish the time and cost for a major pharmaceutical organization. Subsequently, in tranquilize disclosure therapeutic science assumes imperative part yet at the same time the exactness and accuracy of the examination should be enhanced to accomplish least dismissals in the preclinical investigations.
The report offers a far reaching assessment of the market. It does as such by means of top to bottom subjective bits of knowledge, authentic information, and certain projections about market estimate. The projections included in the report have been inferred utilizing demonstrated research strategies and presumptions. Thusly, the exploration report fills in as a store of examination and data for each aspect of the market, including however not constrained to: Regional markets, innovation, sorts, and applications.
Importance & Scope
Significance of recent trends reviews the state of the art and aims to determine the significance of technology and market trends in medicinal chemistry for advancing productivity in drug discovery. One in particular, fragment-based drug design, stands out as promising major improvements in research productivity. After analysis it proves that medicinal chemistry-related approaches and methodologies that drug discovery organizations employ in an effort to increase productivity in early drug discovery. Its key topics considered include structure-based drug design, fragment-based drug design, natural products-based drug design, diversity-oriented synthesis, and chemogenomics. Various ways of computer-aided drug design are also considered, as the complexity and limitations of drug discovery programs that are based on biochemical screens of large compound collections have been major factors in stimulating the growth of this modality.
Why San Francisco, USA?
San Francisco has been a major hub for pharmaceutical companies. It has maintained a stout lead over drug makers in our annual ranking of the largest Bio-Pharma companies in USA.
However, the pharmaceutical market is still dominated by a few very large companies that control the import/distribution, retail and manufacturing sectors.
- Medicinal Chemistry and Drug Discovery
- Principles of Medicinal Chemistry
- Medicinal Chemistry Aspects of Drug Action and Drug Metabolism
- Drug Metabolism
- Molecular Biology - A New Route to Drug Discovery
- Fusion of Traditional And Biomedicine
- Plant Genomics
- Pharmaceuticals Vs Nutraceuticals
- Frontiers In Chemistry
- Computer Aided Drug Designing
- Drug Chemistry
- Hyphenated Chromatographic Techniques
- Cancer Studies: Drug Delivery Chemistry
- Neuro Degenerative Disease
A Unique Opportunity for Advertisers and Sponsors at this International event:
Major Marketing Associations around the Globe
- American Association for Clinical Chemistry
- American Chemical Society
- American Institute of Chemists (AIC)
- American Society of Brewing Chemists
- American Society for Mass Spectrometry
- Royal Society of Chemistry (RSC)
- Swedish Chemical Society
- New Swiss Chemical Society
- Syngenta, Hyderabad Area, India
- DCTG, Beijing City, China
Oceanus Group Ltd, Singapore
Major Marketing Associations in USA
- American Association for Clinical Chemistry
- American Chemical Society
- American Institute of Chemists(AIC)
- American Society of Brewing Chemists
- American Society for Mass Spectrometry
Why to attend???
Meet your target market with members from around the world focused on learning about advertising and marketing, this is your single best opportunity to reach the largest assemblage of participants from all over the world. Conduct demonstrations, distribute information, meet with current and potential customers, make a splash with a new product line, and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in advertising and marketing fields are hallmarks of this conference
USA Pharmaceutical Companies Associated with Advertising and Marketing Activities
The United States is the largest market for pharmaceuticals (including biopharmaceuticals), accounting for around 35 percent of the global market, and is the world leader in biopharmaceutical research and development (R&D). According to the Pharmaceutical Research and Manufacturers Association (PhRMA), U.S. firms conduct the majority of the world's research and development in pharmaceuticals and hold the intellectual property rights on most new medicines. The biopharmaceutical pipeline also has over 7,000 new medicines currently in development around the world with approximately 3,500 compounds currently being studied in the United States - more than any other region around the world. The National Science Foundation reports that the U.S. biopharmaceutical sector accounts for the largest single share of all U.S. business research and development (R&D) investment, representing 23.4 percent of all domestic R&D funded by U.S. business in 2013.
More than 854,000 people work in the biopharmaceutical industry in the United States across a broad range of occupations, such as scientific research, technical support and manufacturing. Directly and indirectly, the industry supports a total of 4.4 million jobs across the United States and added an estimated $1.2 trillion in economic output in 2014, representing 3.8 percent of total U.S. output. The biopharmaceutical industry provides average salaries well above the average for all U.S. workers, and requires a highly-skilled and educated workforce from the administrative level up to and including Ph.D. scientists.
Fast growing segments of the pharmaceutical market include biologics, generics and over-the-counter (OTC) drugs. Biologics now account for over a third of all new drugs in clinical trials or awaiting FDA approval. U.S. generic drug sales reached an estimated $70 billion in 2015, representing a quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favouring generics. OTC market growth will be driven by a growing aging population, consumer trends towards self-medication, and the conversion of drugs from prescription to non-prescription or OTC status.
The United States has one of the world’s most supportive domestic environments for the development and commercialization of pharmaceuticals with minimal market barriers. Its strengths include an intellectual property system that rewards innovation through patent and data protection, a science-based regulatory system that is considered the most rigorous in the world, the world’s largest scientific research base fostered by academic institutions and decades of government research funding, and robust capital markets. enterprises.
In addition, the United States is the world’s largest free-pricing market for pharmaceuticals and has high per capita incomes, a large elderly population, and high rates of chronic diseases and drug consumption. All of these factors ensure that the United States will remain the world’s most important pharmaceutical market for the foreseeable future with healthy growth expected across all product sectors.
Figure 1: Associations and Societies Dealing with Medicinal Chemistry
Figure 2: Companies dealing with Medicinal Chemistry and Drug Delivery
It has been estimated that in the field of Medicinal chemistry more than $79 million has spent in research funding since 2008. The Market report of most of the pharmaceutical companies shows their R&D investments majorly in the following areas, namely:
Advanced Drug Delivery Systems
Excipients in Pharmaceuticals
Ophthalmic Therapeutic Drugs
Skin Disease Treatment
Advanced Drug Delivery Systems:
The global advanced drug delivery market should grow from roughly $178.8 billion in 2015 to nearly $227.3 billion by 2020, with a compound annual growth rate (CAGR) of 4.9%.
The North American market should grow from nearly $75.7 billion in 2015 to $93.4 billion by 2020, a CAGR of 4.3%.
The European market should grow from roughly $57.3 billion in 2015 to nearly $72.1 billion by 2020, a CAGR of 4.7%.
Figure 3: Global Advanced Drug Delivery Market
Pharmaceuticals represented a US$300 bn-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is expected to surpass US$400 bn by 2018, with the ten largest pharmaceutical companies collectively commanding about a third of the market. Companies in the pharmaceutical industry are characterized by their sizeable expenditure on R&D and marketing initiatives in a bid to rake in more revenue. The development of biopharmaceuticals represents a milestone for the industry and personalized therapies carry immense promise in the near future.
- The global market for cancer vaccines totaled $4.5 billion in 2013 and reached nearly $4.0 billion in 2014. This market is expected to reach $4.3 billion by 2019, registering a compound annual growth rate (CAGR) of 1.3% for the period 2014-2019.
- The global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a CAGR of 8.5% from 2014 to 2019.
- The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a CAGR of 12.4% from 2014 to 2019.
Cancer Vaccines: Technologies and Global Markets
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. Extensive promotion and marketing strategies and favourable government support are likely to boost market growth.
The global market for cancer vaccines was valued at nearly $4.2 billion and $4.0 billion in 2014 and 2015, respectively. This market is expected to decline from nearly $3.5 billion in 2016 to $3.4 billion in 2021 at a compound annual growth rate (CAGR) of -0.4% for 2016-2021.
Drug Delivery Companies:
The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. This market is segmented based on route of administration, facility of use, and region.
The drug delivery technology is highly competitive market, comprising of various players. Prominent players in the drug delivery technology market include Johnson & Johnson, Inc. (U.S.), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), Novartis AG (Switzerland), 3M Company (U.S.), Becton, Dickinson and Company (U.S.), GlaxoSmithKline plc, (U.K.), Sanofi (France), and Antares Pharma, Inc. (U.S.).
Nanotechnology Drug Delivery Market
The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.
Key players having presence in the global nanotechnology drug delivery market are AbbVie, Inc., Amgen, Inc., Celgene Corporation, Johnson & Johnson, Merck & Co., Inc., and Novartis International AG, among others.
- Drug Delivery Technology Manufacturers
- Public and Private Physicians
- Healthcare Institutions (Medical Data Centers)
- Research & Clinical Laboratories
- Distributors and Suppliers of Drug Delivery Technologies
- Health Insurance Payers
- Market Research and Consulting Firms
Past Conference Report
MedChem and TDD 2017, USA
We gratefully thank all our wonderful Speakers, Conference Attendees, Students, Media Partners, and Associations for making Medicinal Chemistry and Targeted Drug Delivery 2017 Conference a Successful Event!
The 18th International Conference on Medicinal Chemistry and Targeted Drug Delivery was hosted by the Conference series and was scheduled to held from December 06-08, 2017 at Dallas, USA with the theme “Scientists Unlock Research: Riding Waves in Chemistry, Drug Discovery and Smart Drug Delivery”. The meeting was engrossed in a rich diversified spectrum of comprehensive discussions on novel subjects like Medicinal Chemistry and Drug Discovery, Fusion of Traditional and Biomedicine, Plant Genomics, Pharmaceuticals vs. Nutraceuticals, Computer Aided Drug Designing, Targeted Drug Delivery System-TDDs (smart drug delivery), Drug Chemistry, Hyphenated Chromatographic Techniques, Cancer studies: Drug Delivery Chemistry, Neuro Degenerative Disease, Vaccines and Autism, Emerging Infectious Diseases, Antibiotics, Chem Virology (zika virus), and Novel Research: Hit To Lead
Benevolent response and active participation was received from the Heads, Directors, Scientists, Researchers, Students Groups, Lecturers, Research Associates, Investigators, Readers from Pharmaceutical, Bio-pharmaceutical and Research Institutes working in the field of Medicinal Chemistry who made this event successful.
Conference series expresses its gratitude to the conference Moderator Viviana Rodríguez, Juan Reyna and Martha Hernandez from Universidad Autonoma de Nuevo León, Mexico for taking up the responsibility of coordinating the sessions. Similarly, we also extend our appreciation towards our conference Chairs namely Dr. Tatsuya Takagi, Osaka University Japan, Dr. Victor J. Hruby, University of Arizona USA, Dr. Mitsuji Yamashita, Shizuoka University Japan, Dr. Xiaowei Dong, University of North Texas, USA and Dr. Jung-Mo Ahn ,University of Texas at Dallas, USA
The conference embarked with the opening ceremony followed by Keynote sessions and followed by series of lectures delivered by both Honourable Guests and members of the Keynote forum. The list including:
· Tatsuya Takagi, Osaka University, Japan
· Jung-Mo Ahn ,University of Texas at Dallas, USA
· Victor J. Hruby, University of Arizona,USA
· Xiaowei Dong, University of North Texas, USA
· Mitsuji Yamashita, Shizuoka University
· Jaein Ha, Korea University College of Medicine, Korea
· Hongli Wu ,University of North Texas Health Science Center, USA
· Adebayo A. Adeniyi , South Africa
Conference series offers its heartfelt appreciation to Organizing Committee Members, various outside experts, company representatives and is obliged to other eminent personalities who interlaced with Conferenceseries and supported the conference in every aspect, without which the conference would not have been possible.
Past Reports Proceedings Gallery
All accepted abstracts will be published in respective Conferenceseries International Journals.
Abstracts will be provided with Digital Object Identifier by